{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chimeric+Antigen+Receptor+%28CAR%29+Therapy+Infusion&page=3", "query": { "intervention": "Chimeric Antigen Receptor (CAR) Therapy Infusion", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 220, "total_pages": 22, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chimeric+Antigen+Receptor+%28CAR%29+Therapy+Infusion&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chimeric+Antigen+Receptor+%28CAR%29+Therapy+Infusion&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T07:46:33.636Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02792114", "title": "T-Cell Therapy for Advanced Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Metastatic HER2-negative Breast" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesothelin-targeted T cells", "type": "BIOLOGICAL" }, { "name": "AP1903", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 186, "start_date": "2016-06", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-10T07:46:33.636Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02792114" }, { "nct_id": "NCT03448393", "title": "CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Leukemia, Lymphocytic, B Cell", "B-Cell Lymphoma", "B-Cell Leukemia", "Acute Lymphoid Leukemia", "B-Non Hodgkin Lymphoma", "B-NHL", "B-All", "Acute Lymphoblastic Leukemia", "Acute Lymphocytic Leukemia" ], "interventions": [ { "name": "CD19/CD22 CAR T-Cells", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Apheresis", "type": "PROCEDURE" }, { "name": "Anti-emetic", "type": "OTHER" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "ECG", "type": "DIAGNOSTIC_TEST" }, { "name": "ECHO", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI Brain", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone marrow biopsy", "type": "PROCEDURE" }, { "name": "Cardiac MRI", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "OTHER", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "3 Years to 39 Years" }, "enrollment_count": 54, "start_date": "2018-03-26", "completion_date": "2025-01-13", "has_results": true, "last_update_posted_date": "2025-06-04", "last_synced_at": "2026-10-10T07:46:33.636Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03448393" }, { "nct_id": "NCT04099797", "title": "C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Intrinsic Pontine Glioma", "High Grade Glioma", "Embryonal Tumor", "Ependymal Tumor" ], "interventions": [ { "name": "C7R-GD2.CART cells (IV and ICV infusion)", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "25 Years", "sex": "ALL", "summary": "12 Months to 25 Years" }, "enrollment_count": 56, "start_date": "2020-02-03", "completion_date": "2041-02", "has_results": false, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-10-10T07:46:33.636Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04099797" }, { "nct_id": "NCT06413498", "title": "A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Anitocabtagene Autoleucel", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 452, "start_date": "2024-08-23", "completion_date": "2031-07", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-10T07:46:33.636Z", "location_count": 46, "location_summary": "Gilbert, Arizona • Duarte, California • Los Angeles, California + 35 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06413498" }, { "nct_id": "NCT05993611", "title": "Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Graft Versus Host Disease", "Hematologic and Lymphocytic Disorder", "Steroid Refractory Graft Versus Host Disease" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Chimeric Antigen Receptor T-Cell Therapy", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Electronic Health Record Review", "type": "OTHER" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Tafasitamab", "type": "BIOLOGICAL" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2024-02-19", "completion_date": "2028-05-21", "has_results": false, "last_update_posted_date": "2025-11-13", "last_synced_at": "2026-10-10T07:46:33.636Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05993611" }, { "nct_id": "NCT06121297", "title": "RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Systemic Lupus Erythematosus", "Lupus Nephritis" ], "interventions": [ { "name": "CABA-201", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Cabaletta Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "12 Years to 65 Years" }, "enrollment_count": 28, "start_date": "2024-02-16", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-10T07:46:33.636Z", "location_count": 21, "location_summary": "Orange, California • Sacramento, California • New Haven, Connecticut + 14 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06121297" }, { "nct_id": "NCT04003649", "title": "IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Glioblastoma", "Refractory Glioblastoma" ], "interventions": [ { "name": "IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2019-12-02", "completion_date": "2026-09-26", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-10-10T07:46:33.636Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04003649" }, { "nct_id": "NCT05421663", "title": "A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Lymphoma, B-Cell", "Lymphoma, Large B-Cell, Diffuse" ], "interventions": [ { "name": "JNJ-90014496", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 166, "start_date": "2022-08-12", "completion_date": "2041-07-30", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-10T07:46:33.636Z", "location_count": 14, "location_summary": "Duarte, California • Denver, Colorado • Iowa City, Iowa + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Piscataway", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05421663" }, { "nct_id": "NCT00881920", "title": "Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Myeloma", "Leukemia" ], "interventions": [ { "name": "Kappa CD28 T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2009-07", "completion_date": "2035-07", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-10T07:46:33.636Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00881920" }, { "nct_id": "NCT05634785", "title": "CD30 CAR for CD30+ NSGCT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Germ Cell Tumor", "Nonseminomatous Germ Cell Tumor" ], "interventions": [ { "name": "ATLCAR.CD30 Cells", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamid", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2022-12-09", "completion_date": "2025-12-18", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-10T07:46:33.636Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05634785" } ] }